Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Journal of Clinical Oncology (JCO)
Published September 25, 2026
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma:...
September 26, 2026
Medspoke
Medspoke
The Lancet Oncology
Published September 25, 2026
00:00
--:--
Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility test...
September 26, 2026
Share
Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population.
https://www.medspoke.co/channel_journal?id=686&tap_id=14451
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
The Lancet Oncology
Published September 25, 2026
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone i...
September 26, 2026
Why are you reporting this TALK?
